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Abstract: 
As part of the development of NICE medical technologies guidance on Parafricta 
Bootees and Undergarments to reduce skin breakdown in people with, or at risk of, 
pressure ulcers, the manufacturer (APA Parafricta Ltd) submitted clinical and 
economic evidence which was critically appraised by the External Assessment 
Centre (EAC) and subsequently used by the Medical Technologies Advisory 
Committee to develop recommendations for further research. The University of 
Birmingham and Brunel University, acting as a consortium, was commissioned to act 
as EAC, independently appraising the submission. This article is an overview of the 
original evidence submitted, the EAC's findings and the final NICE guidance. Very 
little comparative evidence was submitted to demonstrate effectiveness of Parafricta 
bootees or undergarments. The sponsor submitted a simple cost analysis to 
estimate the costs of using Parafricta in addition to current practice compared to 
current practice alone, in hospital and community settings separately. The analysis 
took an NHS perspective. The basis of the analysis was a previously published 
comparative study which showed no statistical difference in average lengths of stay 
between those who wore Parafricta Undergarments and Bootees and those who did 
not. The economic model incorporated the costs of Parafricta but assumed shorter 
lengths of stay with Parafricta. The sponsor concluded that Parafricta was cost 
saving relative to the comparators. The EAC made amendments to the sponsor 
analysis to correct for errors and to reflect alternative assumptions. Parafricta 
remained cost saving in most analyses and savings per prevalent case ranged from 
£757 in the hospital model to £3,455 in the community model. All analyses were 
severely limited by the available data on effectiveness, in particular a lack of good 
quality comparative studies.  
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Key points for decision makers 
 The evidence base around the effectiveness of Parafricta Undergarments and Bootees was 
very limited. 
 Analyses based on available evidence suggested that the use of Parafricta Undergarments 
and Bootees in people with or at risk of pressure ulcers was cost-saving to the NHS. 
However, these conclusions have a high degree of uncertainty due to the lack of robust data.  
 More research is needed to confirm the clinical effectiveness assumptions and the scale of 
cost-savings presented in this paper.   
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1. Introduction  
The Medical Technologies Evaluation Programme (MTEP) of the National Institute of 
Health and Care Excellence (NICE) produces evidence-based medical technologies 
guidance with the overall aim of evaluating, and where appropriate encouraging, the 
adoption of novel and innovative medical devices and diagnostic tools within the 
National Health Service (NHS) in England. Manufacturers or distributors of 
potentially eligible technologies notify their products to MTEP. Notified technologies 
must have a CE (Conformité Européenne) mark, or expect one within the next 12 
months, and have the potential to offer significant clinical benefits to patients and the 
NHS at the same cost as current practice or reduce cost with the same clinical 
benefit. Technologies which the Medical Technologies Advisory Committee (MTAC) 
consider to have ‘plausible promise’ to deliver these benefits are selected for full 
evaluation. Guidance is produced after clinical and cost evidence submitted by the 
sponsor is independently assessed by an External Assessment Centre (EAC) and a 
public consultation period. Devices and diagnostic tools with more complex value 
propositions can be routed for evaluation through other NICE programmes such as 
the Diagnostics Assessment Programme or Technology Appraisals.  NICE (2011)1 
describe the methods of MTEP in more detail. This article presents a summary of the 
EAC report for Parafricta Bootees and Undergarments to reduce skin breakdown in 
people with or at risk of pressure ulcers. It is part of a series of NICE Medical 
Technology Guidance summaries being published in Applied Health Economics and 
Health Policy.  
2. Background to the condition and its treatment  
Pressure ulcers (also known as decubitus ulcers or pressure sores) are areas of 
localised skin damage caused by a number of intrinsic and extrinsic factors causing 
skin breakdown. Although anyone can develop a pressure ulcer, patients are at 
increased risk if they have significantly limited mobility (for example, people with a 
spinal cord injury), a previous pressure ulcer, are at risk of nutritional deficiency, are 
unable to reposition themselves or have a neurological condition or significant 
cognitive impairment. Pressure ulcers usually develop in people who have 
underlying health conditions or who have frail skin for whatever reason. Pressure 
ulcers tend to affect people with health conditions that make it difficult to move, 
especially those confined to lying in a bed or sitting for prolonged periods of time. 
They tend to occur more often in the elderly but can occur at any age. Conditions 
that affect the flow of blood through the body, such as type 2 diabetes, can also 
make a person more vulnerable to pressure ulcers. It is estimated that 412,000 
people will develop a new pressure ulcer annually in the NHS2. 
Pressure ulcers can develop when a large amount of pressure is applied to an area 
of skin over a short period of time or when less pressure is applied over a longer 
period of time and tend to develop over bony prominences, particularly heels and the 
sacrum. The extra pressure disrupts the flow of blood through the skin. Without a 
blood supply, the affected skin becomes starved of oxygen and nutrients and begins 
to break down, leading to an ulcer forming. Skin damage is also believed to be 
4 
 
caused by friction, shear and moisture3, but the extent of the contribution of these is 
low – 7.5% in a sample of 28,299 hospital patients4 and 13.9% in a sample of 17,966 
long term care residents5.  
Grading of pressure ulcers is by four grades6: 
 Grade 1 – The affected area of skin appears discoloured and is red in white 
people, and purple or blue in people with darker coloured skin. They do not 
turn white when pressure is placed on them and skin remains intact but may 
hurt or itch. It may also feel either warm and spongy, or hard. 
 Grade 2 – Some of the epidermis or the dermis is damaged, leading to skin 
loss. The ulcer looks like an open wound or a blister. 
 Grade 3 – Skin loss occurs throughout the entire thickness of the skin and the 
underlying tissue is also damaged but muscle and bone are not damaged. 
The ulcer appears as a deep, cavity-like wound. 
 Grade 4 - The skin is severely damaged and the surrounding tissue becomes 
necrotic. The underlying muscles or bone may also be damaged. People with 
grade 4 pressure ulcers have a high risk of developing a life-threatening 
infection. 
For some people, pressure ulcers are an inconvenience that require minor nursing 
care. For others, they can be serious and lead to life-threatening complications such 
as blood poisoning or gangrene. In people with diabetes mellitus they are a cause of 
foot amputations. Pressure ulcers can lead to delayed hospital discharge but it is 
currently unclear as to how much of this is happening in the NHS. It is estimated that 
the cost per patient to heal an ulcer varies from £1,214 for Grade 1, £5,241 for 
Grade 2, £9041 for Grade 3 to £14108 for Grade 47.  
Treatment for pressure ulcers includes regularly changing a person’s position, the 
use of dressings, creams and gels designed to speed up the healing process and 
relieve pressure, and using equipment to protect vulnerable parts of the body, such 
as specially designed mattresses and cushions. Regarding the latter, draft NICE 
guidance states “Pressure redistributing devices are widely accepted methods of 
trying to prevent the development of pressure areas for people assessed as being at 
risk. These devices include different types of mattresses, overlays, cushions and 
seating. They work by reducing pressure, friction or shearing forces. There is limited 
evidence on the effectiveness of these devices”8. For the most serious cases, 
surgery is sometimes recommended. One issue with all pressure relief equipment is 
the impact it has on the patient's ability to self-reposition and move around the bed. 
Much of the equipment currently in use in the NHS addresses the offloading issues 
in pressure ulcer prevention but does not address repositioning. 
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3. The Decision Problem 
3.1 Population 
The target population was any adults or children (excluding very young children) 
with, or at risk of, pressure ulcers, in a hospital or community setting.  
3.2 Intervention  
The intervention was Parafricta which can be one or two Bootees and/or 
Undergarment. Parafricta is made from a proprietary fabric which has a low friction 
coefficient and the intended mode of action is to reduce the friction component of 
skin breakdown. The NICE final scope did not specify whether this referred to a 
single garment only or the use of two or three garments together. Parafricta is used 
as an adjunct to pressure reducing devices used in standard NHS clinical practice.  
3.3 Comparators  
The comparators in the NICE final scope were pressure reducing devices used in 
standard NHS clinical practice, and also one of the following three options:  
1. No Parafricta (i.e. pressure reducing devices alone) 
2. Sheepskin  
3. Pressure-relieving bootees  
3.4 Outcomes  
Relevant outcome measures included: 
  incidence of grade 1 or 2 pressure ulcers progressing to grade 3 or 4 
  incidence of developing pressure ulcers 
  incidence of skin breakdown 
  severity of pressure ulcers  
  length of hospital stay 
  time-to-healing for those who present with an existing pressure ulcer 
  patient compliance with pressure ulcer management interventions 
  patient comfort: including ability to move and self-reposition in bed 
  quality of life 
  morbidity  
  device-related adverse events 
 
4. Review of the clinical and economic evidence 
The sponsor submitted clinical and economic evidence based on the scope issued 
by NICE. The economic evidence included a de novo economic model. The EAC 
critically appraised the submission and carried out additional analyses to evaluate 
the outcomes identified in the scope.  
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4.1 Clinical effectiveness evidence 
4.1.1 Sponsor’s review of clinical effectiveness evidence 
There were seven included studies in the submission, of which three were single 
case studies9,10,11, two were small uncontrolled case series12,13, one was a small 
partially controlled case series14 and one was a larger case series with documented 
historical controls15. There was also an unpublished audit16, which has now been 
published17.  See Table 1 and Table 2 for an overview of these studies. The 
submitted studies evaluated one Parafricta Bootee, one or two Bootees, or 
Undergarments, or a combination of Bootees and Undergarments. The evidence is 
generalizable to the UK setting. 
The three single case studies need no further description, and their results are in 
Table 2. The case series by Loehne (2013)12 gave no information on the study 
design other than that it was a case series of the use of Parafricta Bootees in nursing 
home patients. Stephen-Haynes (2011)13 was a case series of 25 nursing home 
residents evaluating Parafricta Bootees or/and Undergarment added to standard 
approach as outlined by NICE guidance 2005. There was no comparator. Results of 
these studies are also in Table 2.  
Hampton (2009)14 was a case series of 25 nursing home residents. A single 
Parafricta Bootee was used on the right heel in 10 patients, with the left heel used as 
comparator. Eighteen patients had Parafricta Undergarments and there was no 
comparison group.  The duration of follow up was four weeks. The outcomes were 
measured in three ways  
1. Bogginess and redness of skin as assessed by tissue viability nurse  
2. Colour photographs and  
3. High frequency ultrasound graphs.  
The reason for three different ways for measuring outcomes was because of the 
difficulty of assessing skin oedema. Bogginess and redness was judged to be very 
subjectively assessed. Colour photographs did not reproduce the nature of the skin 
damage well as the colour reproduction depended on ambient light levels. The 
ultrasound graphs were an attempt to measure thickening of the skin from oedema 
and were felt to be the most reliable outcome measure and were presented as mean 
pixel number vs intensity. These have not been reproduced because of copyright 
issues. The results suggested that heels with Parafricta bootees became similar to 
normal heels within 4 weeks, and this was suggested to be because of a reduction in 
skin oedema.  
Smith and Ingram 201015 recruited 165 patients in three months, compared with 204 
historical controls recruited in the previous three months of similar conditions in 
same hospital wards (two medical wards and one orthopaedic ward).  All patients 
were at high risk of pressure ulcers (Waterlow score of ≥15), some had pressure 
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ulcers on admission and some did not. All were unable to reposition independently. 
The intervention was the addition of Parafricta Bootee or/and Undergarment to 
standard pressure ulcer preventative measures. Outcomes were the incidence 
improvement and deterioration of pressure ulcers and cost effectiveness. This study 
provided the effectiveness evidence for the economic model. Smith and Ingram 
(2010) analysed results in pressure ulcer incidence, improvement and deterioration 
using differences in incidence. These are reproduced in Table 3. As incidence 
differences are difficult to interpret these were recalculated using relative risks (in 
Revman 5.2) and the results shown in Table 4. The results from the study, whichever 
way it is analysed suggest that the Parafricta cohort had fewer patients who 
developed pressure ulcers in patients without pressure ulcers on admission but no 
difference in the development of additional pressure ulcers in patients who already 
had a pressure ulcer. Also the results suggest that fewer pressure ulcers 
deteriorated in the Parafricta cohort. There were no statistically significant 
differences in length of stay between cohorts 1 and 2 but the lengths of stay were not 
given. The results in Waterlow scores are shown in Table 5.  
The audit at St Helen’s & Knowsley NHS Trust16,17 was of the use of Parafricta 
Bootees for patients considered at risk of a heel pressure ulcer, compared to current 
practice of using a protective hydrogel dressing, which had not been published. This 
audit was started in 2013 and was planned to go on for two years, but the first year’s 
results were available at the time of the appraisal. Gleeson D (2014) was a clinical 
audit of the use of Parafricta Bootees on an unknown number of patients on 6 
hospital wards at St Helens and Knowsley NHS trust between January and 
December 2012 and was submitted as academic-in-confidence material. How it was 
conducted was unclear as there were no details in the manuscript. Characteristics 
and results are in Table 2. This study has since been published (Gleeson 2015) and 
the information remains consistent with that from the unpublished manuscript.  
4.1.2 Critique of clinical effectiveness evidence 
Smith and Ingram 201015 formed the basis of the economic model so is discussed 
further here. It was a case series with historical controls, i.e. a single centre 
controlled before after study. According to the Cochrane Collaboration, a study 
design such as that used in Smith and Ingram (2010) in which there is only one 
intervention or control site, “the intervention (or comparison) is completely 
confounded by study site making it difficult to attribute any observed differences to 
the intervention rather than to other site-specific variables”18 (EPOC 2014).  
Therefore, this study design provides relatively weak comparative evidence as the 
observed results may have been due to confounding.  As no numerical results of 
length of stay by cohort, no numbers of deaths in either cohort and no demographic 
characteristics in either cohort or combined were given, it is impossible to tell how 
similar the cohorts were. The only information available was the Waterlow score from 
the economic submission which suggested that the cohort not given Parafricta may 
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have been more at risk of pressure ulcers than those given Parafricta. The difference 
in pressure ulcers could also be because the Parafricta cohort patients were less ill 
than those in the historical comparison cohort. Therefore, it cannot be inferred that 
any change in pressure ulcer incidence, improvement or deterioration was due to the 
use of Parafricta Bootees and/or Undergarments.    
Additionally, as the patients in the study could not reposition themselves (an 
inclusion criterion for the study) they represented only a subset of the population who 
might potentially benefit from Parafricta.  If patients couldn’t reposition, then 
movement would be limited so it would be likely that any pressure ulcers occurring 
would have been caused by pressure rather than friction. 
4.2 Economic evidence  
4.2.1 Sponsor’s economic submission 
Smith and Ingram (2010) was the single economic study identified in the sponsor 
submission.  This cost-analysis estimated that the use of Parafricta garments may 
reduce the cost of pressure ulcers by £637 per at risk patient admitted to hospital, 
net of the cost of purchase and laundering. Costs were estimated from an NHS 
perspective, but the price base year was not explicitly stated. These savings were 
the result of the estimated reduced length of hospital stay experienced by patients 
using the Parafricta garments. 
The sponsor acquired the raw data on incidence of pressure ulcers and associated 
lengths of stay from this study and used the information as the basis of a new cost 
model.  They used this information to conduct two separate analyses; one in a 
hospital setting and one in a community setting to perform a cost-analysis of the use 
of Parafricta Bootees and Undergarments as an adjunct to other pressure reducing 
devices used as standard in the NHS.  In the hospital model, potential cost savings 
were driven by reductions in length of stay and in the community model by a 
reduction in nurse/carer interventions reflecting lower prevalence of pressure ulcers.  
The hospital model consisted of five potential pathways for patients admitted to 
hospital and at-risk of pressure ulcers: 1. admitted without pressure ulcer(s) and 
remained without; 2. admitted without a pressure ulcer(s), but developed a pressure 
ulcer in hospital; 3. admitted with a pressure ulcer(s) which did not deteriorate, 4. 
admitted with a pressure ulcer(s) which deteriorated and, 5. admitted with a pressure 
ulcer(s) and developed an additional pressure ulcer in hospital. The proportion of 
patients in each potential pathway for both the historical control group and Parafricta 
group is shown in figure 1, depicted as a decision tree. Median length of hospital 
stay for each of the pathways was weighted by incidence.  In the MS Excel 
implementation of the model, relevant per day costs were then applied to relevant 
proportions of weighted stay, based on the expected time to development of an ulcer 
and length of stay.  Costs differ for those days spent without a pressure ulcer, where 
only general hospital costs were incurred, and days with a pressure ulcer. Dressing 
costs and per-day unit costs for hospital stay19 are detailed in table 6.  This analysis 
estimated costs of £5,307 per at-risk patient without the use of Parafricta and £4,550 
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per-risk patient when using parafricta, a cost saving of £757. Some limited sensitivity 
analyses were performed which suggested the results were robust to assumptions.  
The community model used data from the Smith and Ingram study (2010) and 
constituted a steady-state comparison of costs with and without the use of Parafricta. 
Using the incidence of pressure ulcers amongst those patients without an ulcer on 
admission, and the length of stay after development of an ulcer as a proxy for 
duration, the point prevalence with and without the use of Parafricta was estimated. 
It was assumed that without Parafricta, for every patient in the community with a 
pressure ulcer, there will be two other at-risk patients without a pressure ulcer. The 
sponsor stated that this was consistent with published audits of prevalence3,20. Costs 
without Parafricta were then estimated based on the cost of nurse visits/ carer 
interventions (1.86 per week) related to prevalent pressure ulcer cases over a year 
of resource use. The cost without use of Parafricta was £5,899.92 and with use of 
Parafricta £2,444.93, based on a relative prevalence ratio of 0.37.  
4.1.2 Supplementary economic analyses conducted by the EAC 
 
The EAC verified the sponsor’s search strategies and no additional economic studies 
were identified. The EAC validated the sponsor’s economic model and reconstructed 
decision tree for clarity as well as validity check.  
Minor errors in the unit costs used in the Hospital model were encountered and 
rectified, uprating to 2013/14 pounds sterling, where appropriate. A minor modelling 
anomaly that lead to the double counting of some dressing costs was also rectified. 
These changes did not have a substantial impact on results, given the relatively 
small cost of dressings.  The EAC noted that the costs associated with the pathways 
reflecting change in pressure ulcer condition for those admitted with a pressure ulcer 
(pathways 3, 4 and 5) did not incur different costs. This differentiation had the effect 
of diluting data on length of stay, increasing uncertainty. Therefore, the EAC 
presented a slightly modified decision tree, encompassing pathways 3, 4 and 5 into 
one single pathway “Admitted with PU”. (See figure 2) 
The cost of a bed-day in the Hospital model was revisited. The EAC acknowledged 
the difficulty in identifying an appropriate per day cost of “hotel stay” alone, but did 
not feel that the sponsor estimate was sufficiently robust. National Reference Costs21 
for excess bed days were used as a reasonable proxy. The Smith and Ingram (2010) 
paper identified that the at-risk population were treated on general medical wards 
and trauma and orthopaedics wards. The EAC therefore used excess bed days for 
general medicine and trauma, and orthopaedic wards, for the gamut of skin 
disorders (with and without intervention and the whole range of severity) to calculate 
a weighted cost.  The weighted costs are shown in table 7. The sponsor estimate of 
£325 may have been at the higher end of the bed day cost. The EAC model used 
£234 as the base case and ran a sensitivity analysis of £328 as an upper limit.  
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The Sponsor’s model had used median values for length of stay in both the Hospital 
and Community models. Although length of stay results may be skewed, they 
reflected the nature of length of stay as observed in NHS practice; some patients 
require significantly longer time in hospital. It is hard to assume that these longer 
lengths of stay constitute outliers.  For modelling purposes, an arithmetic mean 
would better represent the average length of stay experienced for each of these 
groups and thus the EAC subsequently used mean values in the hospital and 
community cost models.  
After rectifying minor errors, re-estimating bed day costs and modification to the 
structure of the hospital model, supplementary analyses conducted by the EAC 
focused on attempting to account for the two main weaknesses identified in the 
economic modelling included in the submission: 
 Adjusting estimates of patient length of hospital stay for potential confounders. 
 Reflecting uncertainty in input parameters in a more comprehensive manner. 
The EAC was provided with the raw data from Smith and Ingram (2010) by the 
sponsor. The information was reanalysed by the EAC to consider a limited number of 
confounders: patient’s gender, Waterlow score and the ward of admission. A log-
linear model of length of stay was fitted on Parafricta (1/0), gender (male/female), 
Waterlow score (medium/high risk) and location (medical1/medical2/orthopaedic 
ward). Model diagnostic tests confirmed a good fit. As expected, the model was only 
able to explain about 4% of the variation in length of stay, as the potential predictors 
of length of stay were limited.  Nevertheless, it was thought to provide better 
estimates than unadjusted estimates. Lengths of stay and their standard errors for all 
potential pathways were then predicted from the model.  
The EAC version of the hospital model estimated the base-case cost savings to be 
£595, as opposed to the sponsor’s estimate of £757. For the one way sensitivity 
analysis with a bed day costing £328 the costs saving increased to £863. The 
probabilistic sensitivity analysis suggested that in nearly 8 out of 10 occasions the 
use of Parafricta resulted in cost-savings. 
The use of adjusted mean length of stay data fed into the community model, to 
estimate a prevalence ratio. Probabilistic analysis incorporating distributions around 
the time to develop a pressure ulcer and the length of stay was not possible because 
a negative value of the duration of ulcer could be encountered during distribution 
draws. An illustrative deterministic sensitivity analysis using upper and lower 95% 
limits of length of stay was performed to re-estimate cost savings. The EAC version 
estimated the cost savings in the community as £2,510 per annual prevalent case, 
as opposed to £3,455 per annual prevalent case. The deterministic sensitivity 
analysis suggested that the cost-savings could be between £2,295 and £2,799.  
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5. NICE guidance 
5.1 Preliminary guidance 
The evidence submitted by the sponsor and the EAC’s critique of this evidence was 
presented to MTAC who provided draft recommendations relating to Parafricta 
Bootees and Undergarments following their meeting in May 2014.  These were:  
“1.1 Parafricta Bootees and Undergarments show potential to reduce the 
development and progression of skin damage caused by friction and shear in people 
with, or at risk of, pressure ulcers. However, more evidence for their effectiveness in 
clinical practice is needed to support the case for routine adoption of Parafricta 
Bootees and Undergarments in the NHS. 
1.2 Research is recommended to address uncertainties about the claimed patient 
and system benefits of using Parafricta Bootees and Undergarments. This should 
take the form of comparative research against standard care, preferably carried out 
in secondary care for ease and speed of generating findings. The research should 
include development of criteria to recognise people who would most benefit from the 
technology in community and secondary care. NICE will explore the development of 
appropriate further evidence, in collaboration with the technology sponsor and with 
clinical and academic partners, and will review this guidance when substantive new 
evidence becomes available.” 
 
5.2 Consultation response 
During the consultation period NICE received 19 consultation comments from 4 
consultees (3 NHS professionals and 1 manufacturer). The comments concerned 
further academic in confidence data and requests to focus the recommendations on 
the effect of Parafricta Bootees on skin breakdown of the heel in adults only. The 
Committee considered the further academic in confidence data and the suggested 
focus on the effect of the Bootees only. The Committee judged significant 
uncertainties in the evidence base remained and could not recommend routine 
adoption of Parafricta in the NHS. There were therefore few changes made before 
publication of the final NICE guidance. 
 
6. Key challenges and learning points 
Key Challenges: 
 The lack of good quality comparative studies reduced the scope for a robust 
economic analysis 
 Ambiguity in the presentation of sponsor’s submission posed challenges in 
understanding some of the basic ideas and facts used to describe the cost 
model and its inputs 
Learning points: 
 Future studies should collect and record detailed data on potential 
confounding variables 
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 Future submissions should, where possible, provide the raw data on which 
the economic model is based, as having raw data in this appraisal was very 
helpful to test the underlying assumptions and validity of the model   
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Tables and figures: 
Table 1. Comparative studies 
Primary 
study 
(acronym) 
Population Intervention Comparator Outcomes measured and their 
results 
Comment  
Hampton S 
(2009)-  
(JCN2009) 
Case series of 25 nursing 
home residents with grade 2-3 
pressure ulcers on one or 
more heels (10 patients) or the 
sacral area (18 patients). All 
patients had appropriate 
pressure ulcer equipment for 
at least 2 weeks prior to the 
study start. No information on 
ages, medical conditions or 
durations of pressure ulcers. 
Single Parafricta 
Bootee on right 
heel, or 
undergarment 
according to 
damage location 
Duration 4 
weeks but 
unclear whether 
this was for all 
patients.  
For heel: 
comparator was 
patient’s 
untreated left 
heel. 
For sacral ulcers 
– historical 
comparison only 
Skin oedema and damage as 
assessed by:  
1. Bogginess and redness of skin 
as assessed by tissue viability 
nurse  
‘in 100% of the heel cases the 
‘bogginess’ of the skin was 
reduced’ 2. Colour photographs 
3. High frequency ultrasound 
graphs 
These show an apparent 
improvement in the Parafricta 
Bootee’d heels compared to a 
control heel 
Bogginess – subjective 
outcome.  
Colour photograph results not 
presented as they were not 
always representative of nurse 
assessment of the skin.  
Ultrasound – no independent 
validation presented, would 
need to link improvement curve 
shown in graphs presented to 
clinical improvement in the 
patient. Therefore graphs 
difficult to interpret clinically.  
Smith and 
Ingram 
(2010) -  
(JWC2010) 
Case series of 165 patients 
recruited in 3 months, 
compared with 204 historical 
controls (previous 3 months) of 
similar condition in same 
hospital wards (2 medical and 
1 orthopaedic wards, UK 
hospital).  All patients were at 
high risk of pressure ulcers 
(Waterlow score of ≥15), some 
had pressure ulcers on 
admission and some did not. 
All were unable to reposition 
independently.  
Cohort 2. 
Addition of 
Parafricta 
Bootee or/and 
Undergarment 
to standard 
pressure ulcer 
preventative 
measures.   
Historical 
comparison 
Cohort 1: 
standard 
pressure ulcer 
preventative 
measures 
(without the 
addition of 
Parafricta 
Bootees and 
Undergarments) 
For incidence of pressure ulcers 
and deterioration see separate 
table. 
No statistically significant 
differences in length of stay 
between cohorts 1 and 2 
If patients couldn’t reposition 
then movement would be 
limited so likely that pressure 
ulcers caused by pressure 
rather than friction. No 
numerical results of length of 
stay by cohort. No numbers of 
deaths in either cohort. No 
demographic characteristics in 
either cohort or combined. 
Cannot tell how similar the 
cohorts were.  
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Table 2. Case studies or series with no comparative groups fully described 
Primary 
study 
(acronym) 
Population Intervention Comparator Outcomes measured 
and their results 
Comment  
Bree-Aslan 
(2008).  
(NRC3) 
Case study of one nursing 
home diabetic patient 
aged 85 with arterial and 
venous insufficiency and a 
Grade 4 heel pressure 
ulcer measuring 
3.5x3.3cm, being nursed 
on a dynamic air mattress 
and using a soft fibre 
bootee.  
Cavilon spray, 
Hydrogel dressing 
then Versiver 
dressing on top. 
Plus Parafricta 
Bootee over it for 
one week.  
Historical 
comparison 
from the 
same person 
only  
‘marked improvement in 
the wound bed and no 
further damage to the 
surrounding tissues’.  
Impossible to determine whether 
the improvement was temporary or 
permanent or was due to the 
hydrogel dressing, the Parafricta 
Bootee or unrelated to either and 
would have happened anyway.  
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Primary 
study 
(acronym) 
Population Intervention Comparator Outcomes measured 
and their results 
Comment  
Gleeson 
(2014) 
(unpublished 
manuscript) 
(information 
from Gleeson 
2015 in italics)  
Clinical audit of 6 hospital 
wards with patients at high 
risk of pressure ulcers.  
232 Parafricta 
Bootees used with 
unspecified number 
of patients. (for the 
first 6 months, rising 
to 1024 bootees in 
total) 
Also pressure 
reducing/relieving 
products including 
4-sectional electric 
profiling beds, 
pressure-reducing 
foam, alternating air 
mattresses, heel 
troughs and 
cushions. (Some 
patients also given a 
transparent film 
dressing to protect 
the heel) 
Also education and 
training on pressure 
ulcers  
Summary 
historical 
comparison 
only, not 
described 
32% reduction in 
reportable hospital-
acquired grade 2 pressure 
ulcers compared to the 
previous year, presumably 
on these wards. Overall 
there was a Trust-wide 
drop in pressure ulcers of 
76%. There was a 9% 
increase in Trust-wide 
activity in 2012, 
presumably compared to 
2011 
The decrease in pressure ulcers 
was probably not due to a 
decrease in hospital activity but 
may be related to education and 
training initiatives and investment 
in a range of pressure reducing 
products. It is unclear how much of 
this 76% reduction in pressure 
ulcers in the Trust overall was due 
to Parafricta Bootees and how 
much was due to the other 
initiatives taking place at the Trust. 
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Primary 
study 
(acronym) 
Population Intervention Comparator Outcomes measured 
and their results 
Comment  
Hampton S 
(2007)   
(NRC1) 
Case study of one nursing 
home patient aged 82 with 
multiple sclerosis and with 
sore and broken skin over 
the buttocks for several 
months, being nursed on 
an air mattress.   
Parafricta 
Undergarment for 
one week 
Historical 
comparison 
from the 
same person 
only 
‘in less than one week the 
soreness had disappeared 
and the skin was clear’  
Impossible to tell whether the 
improvement was temporary or 
permanent or whether it was due 
to the Parafricta Undergarment or 
would have happened anyway.  
Kerr A (2008).  
(NRC2) 
Case study of one 
nursing home patient 
aged 70 years with poor 
mobility and with at least 
3 month’s history of 
macerated and excoriated 
buttocks with deep split 
wounds and 
inflammation. Sudocreme 
had been applied.  
Parafricta 
Undergarment  
Historical  
comparison 
with 
Sudocreme 
on the same 
person only  
‘reduced inflammation 
with the open areas 
showing signs of closure’  
Impossible to tell whether the 
improvement was temporary or 
permanent or whether it was due 
to the Parafricta Undergarment or 
previous allergy to Sudocreme or 
would have happened anyway. 
Loehne, H.B. 
(2013).   
(SAWC1) 
Case series of an 
unknown number of US 
nursing home patients. No 
information on sex, age, 
current condition, duration, 
grade or site of pressure 
ulcers.  
Excluded were patients 
with, or at risk of, pressure 
ulcers on the heel or foot 
due to pressure only.  
Parafricta Bootee.  
Unclear if both feet 
or only one.  
Dressings (not 
specified) in some 
patients.  
Follow up at 30 
days.  
Unclear.  None of the unknown 
number of patients had 
developed pressure ulcers 
or had re-opening of 
closed wounds.  
This does not present any 
evidence of effectiveness as there 
is minimal information on patients.  
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Primary 
study 
(acronym) 
Population Intervention Comparator Outcomes measured 
and their results 
Comment  
Stephen-
Haynes (2011)  
(WUK2011) 
Case series of 25 nursing 
home patients at-risk of 
pressure ulcers (n=5) or 
with a pressure ulcer (n=20, 
10 with category 1 ulcer, 10 
with category 2 ulcer).  
 
Characteristics included 
steroid use (n=1), CVA 
(n=6), dementia (n=3), 
multiple sclerosis (n=3).  
Parafricta Bootee 
or/and Undergarment 
added to standard 
approach.  
 
None  Skin improvement: 76% 
improvement, 24% same. 
Ease of use: very easy in 
64% patients, easy in 16%, 
fairly easy in 16% and 
difficult in 4%). Garment 
retention: 48% clinicians 
found it very easy to keep 
garments in place, 16% 
easy, 20% fairly easy, 16% 
not easy. Patient comfort: 
76% very comfortable, 24% 
comfortable.  
Impossible to tell whether any 
improvement in pressure ulceration 
was temporary or permanent or 
whether it was due to the Parafricta 
Undergarment or would have 
happened anyway. 
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Table 3. Reported results from Smith and Ingram (2010) 
 Subgroups  Historical controls 
incidence (%) 
Parafricta cohort 
incidence (%) 
% difference  
(Parafricta – 
control ) 
P value  
No pressure ulcer on 
admission  
A, Did not develop a pressure ulcer 67 (59) 58 (75) 16 0.03 
 B. Developed a pressure ulcer  46 (41) 19 (25)   
Pressure ulcer on 
admission  
C. Did not develop an additional 
pressure ulcer  
67 (74) 73 (83) 9 0.18 
 D. Developed an additional pressure 
ulcer  
24 (26) 15 (17)   
Subgroup B.   The pressure ulcer improved  16 (33) 14 (74) 41 0.01 
 The pressure ulcer stayed the same or 
deteriorated 
32 (67) 5 (26)   
Subgroup D.  The pressure ulcer deteriorated  18 (27) 4 (6) -21 0.001 
 The pressure ulcer stayed the same or 
improved  
49 (73) 69 (94)   
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Table 4. Calculated relative risks for Smith and Ingram 2010 
  Cohort 1 (no Parafricta)  Cohort 2 (Parafricta) Relative risk (95%CI)* 
Pressure ulcer on 
admission 
That pressure ulcer 
deteriorated  
18/67 4/73 4.90 (1.75-13.75) 
Pressure ulcer on 
admission  
Developed an additional 
pressure ulcer  
24/91 15/88 1.55 (0.87-2.75) 
     
No pressure ulcer on 
admission  
Developed pressure 
ulcer  
46/113 19/77 1.65 (1.05-2.59) 
No pressure ulcer on 
admission but one 
developed during 
hospital stay  
Pressure ulcer same or 
deteriorated  
32/48 5/19 2.53 (1.16-5.52) 
*Calculated in Revman 5.2 
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Table 5.  Waterlow scores from Smith and Ingram (2010) 
    All incidences     
  
Waterlow 
score  Number  Percentage   
Cohort 1 15-19 103 50.00%   
Pre Parafricta products 20-24 82 39.81%   
  25+ 21 10.19%   
Total    206     
Cohort 2  15-19 94 56.97%   
Post Parafricta products 20-24 52 31.52%   
  25+ 19 11.52%   
Total    165     
       
Chi  Square Test result  P 
value 0.2553898     
  p-value from Chi-square test (implies non-difference if > 0.05) 
 
 
Table 6 Hospital model unit costs 
Unit cost Per day 
cost 
Source 
Bed day £325.00 Sponsor 
assumption 
General 
dressing 
£0.74 Smith and 
Ingram (2010)  
Average 
Mattress cost 
£0.59† Smith and 
Ingram (2010) 
General 
hospital costs 
£326.33 (£325 +£0.74 
+0.59) 
Average PU 
dressing 
£0.74‡ Smith and 
Ingram (2010) 
† (86% mattress @ £0.30, 14% Nimbus @ £2.37), ‡ 
(70% cat 1 dressing @ £0.48, 25% cat 2 dressing @ 
1.11, 5% cat 3 dressing @ £2.59) 
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Table 7 EAC bed-day costs 
  Type of admission 
Ward Elective Non-elective Weighted 
General Medicine  254.2 225.9 226.3 
Skin disorders only 510.2† 222.8 225.7 
Trauma and Orthopaedics 310.1 265.2 274.7 
Skin disorders only 241.2 274.5 271.3 
Combined GM and T&O 302.5 236.1 241.1 
Skin disorders only 327.5 231.4 233.9 
†based on a small numbers of cases (281) 
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Figure 1 
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Figure 2 
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